Managing Difficult Behaviors in the Home and LTC Facility

Download Report

Transcript Managing Difficult Behaviors in the Home and LTC Facility

Approaches to behavioral and psychological symptoms of Dementia

Marie-France Rivard, MD, FRCPC Division of Geriatric Psychiatry University of Ottawa

Objectives

Describe the causes of common psychological and behavioral symptoms in dementia (BPSD)

Introduce the purpose of the PIECES program

Identify appropriate interventions

Advise on the role of pharmacotherapy

Disclosure slide

 Over last 28 years, received honoraria for Continuing education activities from most pharmaceutical companies and some grants for research.  Over last 7 years, no direct funding for research or Continuing Education: honoraria by organizing committees who may have, in turn, received un-restricted grants.  Currently Chair, Seniors Advisory Co to MHCC, mostly volunteer work.

Prevalence of BPSD

90% of patients affected by dementia will experience Behavioral and Psychological Symptoms of Dementia (BPSD) that are severe enough to be labeled as a problem during the course of their illness.

Agitation (75%) Wandering (60%) Depression (50%) Psychosis (30%) Screaming and violence (20%) are most common

Impact of BPSD

 50 – 90% of caregivers considered physical aggression as the most serious problem they encountered and a factor leading to institutionalization. (Rabins et al. 1982)  Front-line staff working in LTC report that physical assault contributes to significant work related stress (Wimo et al. 1997)  Agitation, depression, anxiety, paranoid ideation cause significant suffering.

BPSD Symptom Clusters

Aggression Agitation Apathy Physical aggression Verbal Aggression Aggressive resistance to care Pacing Repetitive actions Dressing/undressing Restless/anxious Withdrawn Lacks interest Amotivation Sad Tearful Hopeless Guilty Anxious Irritable/screaming Suicidal Euphoria Pressured speech Irritable Mania Hallucinations Delusions Misidentification Suspicious Psychosis Depression Adapted from McShane R. Int Psychogeriatr 2000;12(suppl 1): 147

Causes of BPSD What is P.I.E.C.E.S.

 Person-centered assessment and care planning approach, using the care team to develop hypotheses and test the implementation of possible solutions.  An acronym that conveys the individuality and importance of the various factors that contribute to BPSD in dementia.

 These factors are: Physical, Intellectual, Emotional, Capabilities, Environment and Social

P.I.E.C.E.S.

 Taught in Ontario since 1998 to LTC registered staff  From 1999-2007 expanded to include administrators of LTC, unregistered staff, acute care hospitals, CCAC case managers  2007-08: PIECES program for physicians:   Soon available for distribution To be tested with family health teams and utilized by Peer Presenters and Preceptors of Ontario’s Alzheimer strategy

Why use the P.I.E.C.E.S. approach?

 Identification of target behaviors which present risk or urgency  Flags possible delirium  Framework for synthesis of non pharmacologic approaches  Nutrition, comfort, hydration, sleep, etc…  Environment, personhood, social, stimulation  Guide the pharmacologic approach

PIECES Template

 The Three Question Template  1. What has changed?

 2. What are the RISKS and possible causes (using the PIECES framework)?

 3. What is/are the action (s)?

P -

Physical

 Drugs   Anticholinergics, benzos, Include OTC, alcohol  Disease  Atypical presentations, hypoxia, pain, infections  Delirium – 30% mortality if undetected  Hypoactive and hyperactive  Basics  Hydration, bowels, bladder, fatigue, sleep

 I – infectious

Delirium

     W - withdrawal A – acute metabolic, dehydration, renal, bowels T –toxins, drugs C – CNS pathology H – hypoxia,  D - deficiencies   E - endocrine A – acute vascular   T - trauma H – heavy metals

Delirium work up and intervention

 History and physical  Bowel/bladder/pain/mobility  Caregivers re what has changed  Review medications including prns  Investigations to identify and correct underlying causes:    Vitals, O2 sat, glucose, chest X-ray CBC, Na, K, Creatinine, Albumin, Drug levels, Ca, Mg, TSH, B12, Folate, Urine, etc….

CT head if warranted

Intellectual/cognitive changes

Memory loss, Amnesia:

Annoying repetitive questioning.

 

Accusing others of not telling them about upcoming events.

Being “uncooperative” with previous requests.

Agnosia

  

Accusing family member of being an imposter when cannot quite recognize face… Failing to recognize one’s image in the mirror.

Utilizing objects inappropriately.

Intellectual/cognitive changes

Apraxia

Dressing inappropriately —upset with assistance provided/required

Needing assistance to eat

Aphasia

  

Frustration/anxiety Inappropriate requests/comments Reacting concretely to abstract concept

Intellectual/cognitive changes

Anosognosia

Not recognizing that one is no longer knows about or how to do some things, being unaware of deficits and need for help

Impaired executive functions:

poor planning/initiation

unable to appreciate consequences of things said or done before saying/doing them, impulsive behavior

Return to a place back in time

Intellectual/cognitive changes

Perceptual difficulties (distances, depth, time elapsed, gaps)

 

Resisting a bath or toileting, running over others.

Apathy and “perseveration”

May be confused with depression or “ill-will”.

Return of primitive reflexes, perseverative behaviors

Grabbing caregiver’s clothing or body part and being unable to let go.

E - Emotions

 Delusions/Hallucinations/agitation  Dopamine and cholinergic mediated  Depression/irritability/anxiety  Serotonergic, adrenergic, cholinergic mediated.

 Adjustment Disorder  Reactivation of past psychiatric illness with stress of dementia, placement  Emotional Memory, past trauma, losses

C - Capabilities

    Balance of Physical Demands and Capabilities Capacities too low to do a task?

 Resistive behaviours, Frustration   Catastrophic reactions Withdrawal Able to do more but assumed incapable  Boredom, “attention-seeking” behaviors Be sensitive to changes in function  Acute change – rule out reversible component  Gradual change – Adapt care to progression of dementia

E - Environment

Environmental structure

 design, lighting (glare), physical space, temperature 

Ambience

 Sounds, smells, colour, noise  

Familiarity Noise

– excessive, distressing, confusing, unfamiliar  Over/under stimulation  Changing environment  Relocation, routines, caregivers

S - Social

Life story, life accomplishments

‘All about me’, personhood

Social network

Relationships of family

Lifelong coping strategies

Interactions with caregivers who may not know you as a person

Interaction with other residents, roommates, others with dementia…

P.I.E.C.E.S. tools

 Daily Observation Sheet (DOS), A-B-C charting  Shows frequency, severity, patterns of behaviours, can be individualized  Cohen Mansfield Agitation Inventory (CMAI)  Identifies behaviours and severity over 7 day period  Confusion Assessment Method (CAM)  Delirium screen  MMSE, MOCA, Clock  Sig: E Caps, Cornell Depression Scale

DOS Behavior Map

SAT Time 6am 7am 8am 9am 10a 11a 12p 1pm 2pm 3pm 4pm MON TUE WED THU FRI SUN

Other Common Tools

Scale Assessment

CMAI

The Cohen-Mansfield Agitation Inventory

NPI-NH

Neuro-psychiatric Inventory Nursing Home Version

BEHAVE-AD

The Behavioral Pathology in Alzheimer’s Disease Rating Scale 29 agitated behaviors rated by caregiver on 7 point frequency scale 12 items rated by caregiver on a 4 point frequency and a 3 point severity scale 25 symptoms rated by caregiver on a 4 point severity scale

Caregiver Scales

 Useful for patients in the community  Self report can be used in office setting or home visit  Allow caregivers to identify behaviours they may not be comfortable talking about in front of their loved one  ie - Kingston Behavioural Assessment

Pharmacological treatment

Clear indication, potential benefits

Expected time to response

Risks associated with and without Rx

Appropriate dose range

Monitoring for side effects and response

When to consider dose reduction, discontinuation.

Top Ten Behaviors not (usually) responsive to medication

 Aimless wandering  Inappropriate urination /defecation  Inappropriate dressing /undressing  Annoying perseverative activities  Vocally repetitious behavior  Hiding/hoarding  Pushing wheelchair bound co-patient  Eating in-edibles  Inappropriate isolation  Tugging at/ removal of restraints

Top Ten Behaviors responsive (perhaps!) to medication

 Physical aggression  Verbal aggression  Anxious, restless  Sadness, crying, anorexia  Withdrawn, apathetic  Sleep disturbance  Wandering with agitation/aggression  Vocally repetitious behavior  Delusions and hallucinations  Sexually inappropriate behavior with agitation

Pharmacological treatment: When (indications)

   

Behaviors that have not responded to non pharmacological treatment.

Persistent despite P.I.E.C.E.S. approach Imminent and severe risk to self or others

E.g. delirium needing to be investigated Behaviors that can respond to medication: listed previously Target appropriate symptom cluster: depression, anxiety (acute or chronic), difficulty falling asleep, psychosis…

Pharmacological treatment: Choosing best drug

   

Correct underlying cause, deficiency:

Optimize treatment of dementia, CEIs, memantine Target appropriate symptom cluster:

    

Depression: Antidepressant Anxiety (longer term): antidepressant Difficulty falling asleep: Trazodone Psychosis: antipsychotic Aggression: antipsychotic Choose least likely to worsen dementia and medical problems

E.g. Least anticholinergic Choose drugs without problematic interaction

Best choices: antidepressants

   

SSRI for depression or anxiety

Citalopram (Celexa) and Escitalopram (Cipralex)

Sertraline (Zoloft) When noradrenergic properties may be wanted (pain, activation)

 

Venlafaxine (Effexor XR) *not if unstable BP Bupropion (not if unstable BP) When sedation may be needed urgently

 

Trazodone *watch for hypotension Mirtazapine (some anticholinergic properties) When important to have a drug well tolerated

Moclobemide (Manerix) * drug interactions

Best Choices - anxiety

 Cholinesterase inhibitor  particularly for anxiety of early dementia.

 SSRIs  first line treatment for anxiety disorders  will take a few weeks to work  check drug interactions.  Consider trazodone (watch for hypotension)

Best choices: anti-psychotics

 

For acute delirium – very short term (days)

 

Haloperidol (0.5 mg that may be repeated) Loxapine (2.5 mg that may be repeated) For persistent psychosis/agitation

  

Risperidone (Risperdal): start with 0.25-0.5 mg daily and increase slowly as needed/tolerated over weeks to max. 2 mg per day Olanzapine (Zyprexa): start with 2.5 mg daily and increase slowly as needed/tolerated over weeks, to max 10 mg daily Quetiapine (Seroquel): start with 12.5 mg daily or BID and increase slowly over weeks to max 200 mg daily

Target Symptoms Delusions Hallucination Aggression “Agitation” Sadness Irritability Anxiety Insomnia

Meds for BPSD

Medication Starting Dose (mg/day) Average Target Dose (mg/day) Atypical Antipsychotics:

  

risperidone olanzapine quetiapine 0.25-0.5

2.5-5 12.5-25 Antidepressants

citalopram

sertraline

venlafaxine

mirtazapine

trazodone 10 25 37.5

7.5

12.5-25 0.5-2.0

2.5-7.5

50-400 10-40 50-100 37.5-225 15-45 50-100

Meds for BPSD

Target symptoms Medication Starting Dose (mg/day) Average Target Dose (mg/day)

Mood swings

Euphoria

Impulsivity

Agitation

Apathy

Irritability

Anxiety (short term use in predictable situations) Mood stabilizers:

valproic acid

carbamazepine 250 50-100 As directed Cholinesterase Inhibitors.

Memantine Anxiolytics:

lorazepam

oxazepam 5 mg daily 0.25-0.5

5-10 500-1000 300-800 As directed 10 mg BID 0.5-1.5

10-30

Risks present when there is no pharmacological Rx

Risks of injury (self and others), exhaustion, severe and prolonged suffering, increased risk of death with depression, etc.

Need to present the risks of not treating with medications to pt or SDM when obtaining informed consent.

Risks associated with pharmacological Rx

  

Risks of antidepressants:

   

Hyponatremia Increased agitation/insomnia/suicide in first few weeks GI upset and bleed if previous ulcers Headaches Risks of anti-psychotics

  

Increase risk of death (all antipsychotics), increased QT, cerebrovascular accident EPS and tardive dyskinesia Worsening of vascular risk factors (increased weight, lipids, diabetes) Risks of benzodiazepines:

Falls, ataxia, worsening dementia, memory, disinhibition

Using minimal effective dose, only for the duration required

Consider dose reduction for antipsychotic as soon as there is clear therapeutic response to prevent development of side effects

Review anti-psychotic medication for possible discontinuation Q 6 months

Maintain full dose of antidepressant but review if still needed after 1-2 years? Only if no prior history of depression

Family physicians are at the core of the treatment team, working with:

Patients and substitute decision makers

Other caregivers (home care, LTC staff)

Community resources (Alzheimer Society, First Link programs)

Consultants such as PRCs, Outreach teams, Specialized geriatric medicine and mental health services

Questions and further readings

Program for physicians should be available in the coming months: distribution strategies?

CCSMH guidelines on LTC issues, depression, delirium and suicide

New Canadian Consensus guidelines on Dementia.